Brought to you by 
Aquinox Pharmaceuticals nets $43mm through its IPO
14 Sep 2020
Executive Summary
Aquinox Pharmaceuticals Inc., focused on developing SHIP1 (SH2-containing inositol phosphatase) activators for cancer and inflammation as well as respiratory, GI, and neurological conditions, netted $43mm through its initial public offering. The company sold 4.2mm common shares at $11,the mid-point of its $10-12 range, up from the 3.7mm shares it had originally hoped to sell.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aquinox Pharmaceuticals nets $43mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice